2seventy bio Announces Upcoming Investor Events
2seventy bio, the upcoming oncology spin-off from bluebird bio (NASDAQ: BLUE), has announced a series of investor events to discuss its research pipeline and strategic direction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
-
September 21, 2021 ,11:00am-12:00pm ET
-
-
Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
-
September 22, 2021 ,1:00-2:00pm ET
-
To access the live webcasts and dial-in information for 2seventy bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005440/en/
Investors & Media
Investors:
epingpank@bluebirdbio.com
Media:
jsnyder@bluebirdbio.com
Source: bluebird bio